Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 12/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616134 | 0.89 | TSHR (0.51) | TSHRHCAR3CASP6LMNA | |
| SCHEMBL7404809 | 0.89 | TSHR (0.51) | TSHRHCAR3CASP6LMNA | |
| SCHEMBL11463892 | 0.82 | HCAR3 (0.54) | TSHRHCAR3CASP6NQO2MAPT | |
| SCHEMBL19451787 | 0.82 | HCAR3 (0.68) | HCAR3ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL2441139 | 0.81 | NQO2 (0.48) | TSHRNQO2ALDH1A1MAPT | |
| SCHEMBL19058450 | 0.81 | HCAR3 (0.52) | TSHRHCAR3CASP6ALDH1A1MAPT | |
| SCHEMBL30408678 | 0.81 | NQO2 (0.53) | TSHRNQO2ALDH1A1NPC1RAB9A | |
| SCHEMBL6682212 | 0.81 | NQO2 (0.53) | TSHRNQO2ALDH1A1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL23228026 | 0.81 | HCAR3 (0.67) | HCAR3ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL18944165 | 0.80 | ALDH1A1 (0.41) | TSHRHCAR3ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | disclosed |
| EP-1934181-A2 | KINASE INHIBITORS | Devgen NV (BE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042321-A2 | KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | ROCK1, MAP3K1, MAP3K11 | TSHR 1584/4885HCAR3 996/4885CASP6 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.